Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).
Fujitani K, Tamura S, Kimura Y, Matsuyama J, Imamura H, Yamamoto K, Fujita J, Iijima S, Ueda S, Kurokawa Y, Shimokawa T, Satoh T; Osaka Gastrointestinal Cancer Chemotherapy Study Group. Fujitani K, et al. Among authors: matsuyama j. Gastric Cancer. 2020 May;23(3):520-530. doi: 10.1007/s10120-019-01023-w. Epub 2019 Oct 30. Gastric Cancer. 2020. PMID: 31667688 Clinical Trial.
Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
Kawakami H, Fujitani K, Matsuyama J, Akamaru Y, Tamura S, Endo S, Kimura Y, Makari Y, Tamura T, Sugimoto N, Sakai D, Tsujinaka T, Goto M, Kurokawa Y, Shimokawa T, Satoh T; Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG). Kawakami H, et al. Among authors: matsuyama j. Int J Clin Oncol. 2020 Sep;25(9):1635-1643. doi: 10.1007/s10147-020-01711-z. Epub 2020 Jun 3. Int J Clin Oncol. 2020. PMID: 32494981 Clinical Trial.
Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3).
Kurokawa Y, Matsuyama J, Nishikawa K, Takeno A, Kimura Y, Fujitani K, Kawabata R, Makari Y, Terazawa T, Kawakami H, Sakai D, Shimokawa T, Satoh T. Kurokawa Y, et al. Among authors: matsuyama j. Gastric Cancer. 2021 Mar;24(2):428-434. doi: 10.1007/s10120-020-01112-1. Epub 2020 Aug 10. Gastric Cancer. 2021. PMID: 32779034 Clinical Trial.
A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
Tamura S, Taniguchi H, Nishikawa K, Imamura H, Fujita J, Takeno A, Matsuyama J, Kimura Y, Kawada J, Hirao M, Hirota M, Fujitani K, Kurokawa Y, Sakai D, Kawakami H, Shimokawa T, Satoh T. Tamura S, et al. Among authors: matsuyama j. Int J Clin Oncol. 2020 Dec;25(12):2035-2043. doi: 10.1007/s10147-020-01768-w. Epub 2020 Sep 14. Int J Clin Oncol. 2020. PMID: 32926227 Free PMC article. Clinical Trial.
Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701.
Kawase T, Imamura H, Goto M, Kimura Y, Ueda S, Matsuyama J, Nishikawa K, Sugimoto N, Fujita J, Tamura T, Fukushima N, Kawakami H, Sakai D, Kurokawa Y, Shimokawa T, Satoh T. Kawase T, et al. Among authors: matsuyama j. Int J Clin Oncol. 2021 Oct;26(10):1871-1880. doi: 10.1007/s10147-021-01984-y. Epub 2021 Aug 28. Int J Clin Oncol. 2021. PMID: 34453640 Clinical Trial.
Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).
Matsuyama J, Terazawa T, Goto M, Kawabata R, Endo S, Imano M, Fujita S, Akamaru Y, Taniguchi H, Tatsumi M, Lee SW, Kawakami H, Kurokawa Y, Shimokawa T, Sakai D, Kato T, Fujitani K, Satoh T. Matsuyama J, et al. Oncologist. 2022 Apr 5;27(4):251-e304. doi: 10.1093/oncolo/oyab061. Oncologist. 2022. PMID: 35380725 Free PMC article. Clinical Trial.
Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials.
Kimura Y, Kawakami H, Tamura S, Fujitani K, Matsuyama J, Imamura H, Iijima S, Sakai D, Kurokawa Y, Shimokawa T, Tsujinaka T, Furukawa H, Satoh T. Kimura Y, et al. Among authors: matsuyama j. Gastric Cancer. 2023 Sep;26(5):788-797. doi: 10.1007/s10120-023-01408-y. Epub 2023 Jun 19. Gastric Cancer. 2023. PMID: 37335367
Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902).
Kawase T, Imamura H, Kawabata R, Matsuyama J, Nishikawa K, Yanagihara K, Yamamoto K, Hoki N, Kawada J, Kawakami H, Sakai D, Kurokawa Y, Shimokawa T, Satoh T. Kawase T, et al. Among authors: matsuyama j. Int J Clin Oncol. 2024 Feb;29(2):134-141. doi: 10.1007/s10147-023-02437-4. Epub 2024 Jan 16. Int J Clin Oncol. 2024. PMID: 38227090 Clinical Trial.
Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.
Tamura S, Fujitani K, Kimura Y, Tsuji T, Matsuyama J, Iijima S, Imamura H, Inoue K, Kobayashi K, Kurokawa Y, Furukawa H; Osaka Gastrointestinal Cancer Chemotherapy Study Group. Tamura S, et al. Among authors: matsuyama j. Oncology. 2011;80(5-6):296-300. doi: 10.1159/000329090. Epub 2011 Jul 18. Oncology. 2011. PMID: 21778769 Clinical Trial.
192 results